J Greenhalgh

2.7k total citations
62 papers, 1.8k citations indexed

About

J Greenhalgh is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, J Greenhalgh has authored 62 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Cardiology and Cardiovascular Medicine and 13 papers in Oncology. Recurrent topics in J Greenhalgh's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Pharmacological Effects and Toxicity Studies (9 papers). J Greenhalgh is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Pharmacological Effects and Toxicity Studies (9 papers). J Greenhalgh collaborates with scholars based in United Kingdom, Denmark and Australia. J Greenhalgh's co-authors include Y Dündar, Anthony G Marson, Angela Boland, Jennifer Weston, Catrin Tudur Smith, Naghme Adab, Rebecca Bromley, Andrew McKay, A Bagust and Rumona Dickson and has published in prestigious journals such as PLoS ONE, Cochrane Database of Systematic Reviews and Annals of Oncology.

In The Last Decade

J Greenhalgh

59 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J Greenhalgh United Kingdom 25 512 457 427 374 331 62 1.8k
Ellen Ruud Norway 31 1.0k 2.0× 99 0.2× 721 1.7× 324 0.9× 437 1.3× 119 2.4k
Cecilie E. Kiserud Norway 24 710 1.4× 180 0.4× 418 1.0× 295 0.8× 942 2.8× 119 1.8k
Amnon Lahad Israel 25 374 0.7× 150 0.3× 214 0.5× 245 0.7× 142 0.4× 61 2.4k
Peter D. Donofrio United States 29 212 0.4× 311 0.7× 165 0.4× 135 0.4× 137 0.4× 73 2.9k
Peter D. Cole United States 29 827 1.6× 76 0.2× 915 2.1× 570 1.5× 567 1.7× 135 2.6k
John H. Ward United States 29 153 0.3× 201 0.4× 154 0.4× 291 0.8× 588 1.8× 74 2.3k
Martina E. Schmidt Germany 31 842 1.6× 190 0.4× 265 0.6× 711 1.9× 2.0k 6.0× 104 2.9k
Christine Smith United Kingdom 13 321 0.6× 278 0.6× 176 0.4× 89 0.2× 62 0.2× 28 1.2k
Ingrid A. Holm United States 33 799 1.6× 72 0.2× 754 1.8× 280 0.7× 373 1.1× 116 4.3k
Carol Blendowski United States 5 504 1.0× 248 0.5× 105 0.2× 467 1.2× 930 2.8× 6 1.8k

Countries citing papers authored by J Greenhalgh

Since Specialization
Citations

This map shows the geographic impact of J Greenhalgh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Greenhalgh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Greenhalgh more than expected).

Fields of papers citing papers by J Greenhalgh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Greenhalgh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Greenhalgh. The network helps show where J Greenhalgh may publish in the future.

Co-authorship network of co-authors of J Greenhalgh

This figure shows the co-authorship network connecting the top 25 collaborators of J Greenhalgh. A scholar is included among the top collaborators of J Greenhalgh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Greenhalgh. J Greenhalgh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fleeman, Nigel, Rachel Houten, Sarah J Nevitt, et al.. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 28(49). 1–190.
2.
3.
Adab, Naghme, Jill Clayton‐Smith, Jakob Christensen, et al.. (2023). Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child. Neurotoxicology and Teratology. 98. 107243–107243. 12 indexed citations
4.
Bresnahan, Rebecca, Rachel Houten, J Greenhalgh, et al.. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 7(4). 525–536.
5.
Fleeman, Nigel, Rachel Houten, A Bagust, et al.. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technology Assessment. 24(2). 1–180. 30 indexed citations
6.
Fleeman, Nigel, Rachel Houten, Marty Chaplin, et al.. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer. 19(1). 1209–1209. 34 indexed citations
7.
Duarte, Rui, Angela Stainthorpe, J Greenhalgh, et al.. (2019). The clinical and cost effectiveness of lead-I electrocardiogram (ECG) devices for detecting atrial fibrillation using single-time point testing in primary care: a systematic review and economic evaluation. Health Technology Assessment. 1 indexed citations
8.
Duarte, Rui, Angela Stainthorpe, James Mahon, et al.. (2019). Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation. PLoS ONE. 14(12). e0226671–e0226671. 17 indexed citations
9.
Stainthorpe, Angela, J Greenhalgh, A Bagust, et al.. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 36(10). 1153–1163. 11 indexed citations
10.
Duarte, Rui, James Mahon, Sarah J Nevitt, et al.. (2018). Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 37(3). 345–357. 7 indexed citations
11.
Bromley, Rebecca, Jennifer Weston, Naghme Adab, et al.. (2014). Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews. 2020(6). CD010236–CD010236. 192 indexed citations
12.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2014). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics. 33(2). 137–148. 14 indexed citations
13.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2013). Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma. PharmacoEconomics. 31(5). 403–413. 24 indexed citations
14.
Pulman, Jennifer, J Greenhalgh, & Anthony G Marson. (2013). Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database of Systematic Reviews. CD007286–CD007286. 33 indexed citations
15.
Cherry, Mary Gemma, J Greenhalgh, Leeza Osipenko, et al.. (2012). The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.. Health Technology Assessment. 16(43). 1–129. 34 indexed citations
16.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technology Assessment. 15(31). 1–178. 25 indexed citations
17.
Greenhalgh, J, et al.. (2010). Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention. Appetite. 56(2). 375–385. 72 indexed citations
18.
Bagust, A, J Greenhalgh, Angela Boland, et al.. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. PharmacoEconomics. 28(6). 439–448. 36 indexed citations
19.
Greenhalgh, J, Rumona Dickson, & Y Dündar. (2010). Biofeedback for hypertension: a systematic review. Journal of Hypertension. 28(4). 644–652. 21 indexed citations
20.
Greenhalgh, J, et al.. (2009). Positive- and negative peer modelling effects on young children's consumption of novel blue foods. Appetite. 52(3). 646–653. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen Ruud Breakdown of academic impact, for papers by Cecilie E. Kiserud Breakdown of academic impact, for papers by Amnon Lahad Breakdown of academic impact, for papers by Peter D. Donofrio Breakdown of academic impact, for papers by Peter D. Cole Breakdown of academic impact, for papers by John H. Ward Breakdown of academic impact, for papers by Martina E. Schmidt Breakdown of academic impact, for papers by Christine Smith Breakdown of academic impact, for papers by Ingrid A. Holm Breakdown of academic impact, for papers by Carol Blendowski
Rankless by CCL
2026